Pasar al contenido principal

ESTUDIO DEL PAPEL REGULADOR DE LA TRANSMISION DE FUERZA ENTRE LA MATRIZ ESTRACELULAR Y EL NUCLEO EN LA MECANOTRANSDUCCION

PID2022-142672NB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Micro Immune Response On-chip (MIRO) models the tumour-stroma interface for immunotherapy testing

  • Perucca, Alice
  • Gómez-Llonín, Andrea
  • Rivas, Elisa
  • Linares, Jenniffer
  • Garrido, Marta
  • Sallent-Aragay, Anna
  • Recort-Bascuas, Alba
  • Comerma Blesa, Laura, 1983-
  • Rovira, Ana
  • Albanell Mestres, Joan
  • Calon, Alexandre
  • Labernadie, Anna
Immunotherapies are beneficial for a considerable proportion of cancer patients, but ineffective in others. In vitro modelling of the complex interactions between cancer cells and their microenvironment could provide a path to understanding immune therapy sensitivity and resistance. Here we develop MIRO, a fully humanised in vitro platform to model the spatial organisation of the tumour/stroma interface and its interaction with immune cells. We find that stromal barriers are associated with immune exclusion and protect cancer cells from antibody-dependent cellular cytotoxicity, elicited by targeted therapy. We demonstrate that IL2-driven immunomodulation increases immune cell velocity and spreading to overcome stromal immunosuppression and restores anti-cancer response in refractory tumours. Collectively, our study underscores the translational value of MIRO as a powerful tool for exploring how the spatial organisation of the tumour microenvironment shapes the immune landscape and influences the responses to immunomodulating therapies., We thank S. Usieto, S. Menendez Romero, D. Zafra Puerta, A. Menendez, D. Izquierdo Garcia, C. Rols, J. Durand for their technical assistance. A.L. acknowledges funding from “La Caixa” Banking Foundation (LCF/BQ/PR18/11640001) and from the Spanish Ministry for Science and Innovation MICIU/AEI /10.13039/501100011033 and “ERDF-EU A way of making Europe”, (PID2021-128635NB-I00), and “ESF Investing in your future”, (RYC2020/029736/I). This work was also supported by grants from Instituto de Salud Carlos III (ISCIII) co-funded by the European Union (EU) (PI17/00211, CP16/00151, PI20/00011; Spanish Ministry of Economy and Competitiveness) to A.C. A.C. is the recipient of Miguel Servet research contracts from Instituto de Salud Carlos III co-funded by the European Union (MS16/00151, CPII21/00012). J.A. acknowledges funding from the Generalitat de Catalunya (AGAUR 2021 SGR 00776), the CIBERONC (CB16/12/00241), and the ISCIII co-funded by the EU (PI21/00002). This work was also supported by the Plan de Recuperación, Transformación y Resiliencia (CNS2023-145267) co-funded by the European Union to A.C. P.R.-C. acknowledges funding from the Spanish Ministry of Science and Innovation (PID2022-142672NB-I00), the European Research Council (AdG 101097753), the Generalitat de Catalunya (2017-SGR-1602), and the prize ‘ICREA Academia’ for excellence in research. X.T. acknowledges funding from the Generalitat de Catalunya (AGAUR SGR-2017-01602), the CERCA Programme, the Spanish Ministry for Science and Innovation MICCINN/FEDER (PID2021-128635NB-I00 MCIN/AEI/ 10.13039/501100011033 and “ERDF-EU A way of making Europe”), European Research Council (Adv-883739), Fundació la Marató de TV3 (project 201903-30-31-32), European Commission (H2020-FETPROACT-01-2016-731957), La Caixa Foundation (LCF/PR/HR20/52400004 and ID 100010434 under the agreement LCF/PR/HR20/52400004); IBEC and IRB are recipient of a Severo Ochoa Award of Excellence from the MINECO. This work was also supported by Grant PT20/00023, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and the “Xarxa de Bancs de tumors” sponsored by Pla Director d’Oncologia de Catalunya (XBTC).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nucleocytoplasmic transport senses mechanical forces independently of cell density in cell monolayers

  • Granero-Moya, Ignasi
  • Venturini, Valeria
  • Belthier, Guillaume
  • Groenen, Bart
  • Molina-Jordán, Marc
  • González-Martín, Miguel
  • Trepat, Xavier
  • Rheenen, Jacco van
  • Andreu, Ion
  • Roca-Cusachs, Pere
Cells sense and respond to mechanical forces through mechanotransduction, which regulates processes in health and disease. In single adhesive cells, mechanotransduction involves the transmission of force from the extracellular matrix to the cell nucleus, where it affects nucleocytoplasmic transport (NCT) and the subsequent nuclear localization of transcriptional regulators, such as YAP (also known as YAP1). However, if and how NCT is mechanosensitive in multicellular systems is unclear. Here, we characterize and use a fluorescent sensor of nucleocytoplasmic transport (Sencyt) and demonstrate that NCT responds to mechanical forces but not cell density in cell monolayers. Using monolayers of both epithelial and mesenchymal phenotype, we show that NCT is altered in response both to osmotic shocks and to the inhibition of cell contractility. Furthermore, NCT correlates with the degree of nuclear deformation measured through nuclear solidity, a shape parameter related to nuclear envelope tension. In contrast, YAP is sensitive to cell density, showing that the YAP response to cell-cell contacts is not via a mere mechanical effect of NCT. Our results demonstrate the generality of the mechanical regulation of NCT., We acknowledge funding from the ‘la Caixa’ Foundation (grant LCF/PR/HR20/52400004 to X.T., J.v.R., and P.R.-C. and fellowships LCF/BQ/DR19/11740009 to I.G.-M. and LCF/BQ/DR19/11740009 to M.M.J.), the Spanish Ministry of Science and Innovation (PID2022-142672NB-I00 to P.R.-C., PID2021-128635NB-I00 to X.T. and PID2022-141040NA-I00 to I.A.), the Generalitat de Catalunya (2021 SGR 01425 to X.T. and P.R.-C.), the prize ‘ICREA Academia’ for excellence in research to P.R.-C., Fundació la Marató de TV3 (201936-30-31 to P.R.-C.), the European Research Council (grant 101097753 MechanoSynth to P.R-C. and Adv-883739 Epifold to X.T.), and The Basque Government (grant PIBA_2023_1_0033 to I.A.). This work was also supported in part by the Fundación Biofísica Bizkaia and the Basque Excellence Research Centre (BERC) program of the Basque Government. Open Access funding provided by Universitat de Barcelona. Deposited in PMC for immediate release., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Micro Immune Response On-chip (MIRO) models the tumour-stroma interface for immunotherapy testing

  • Perucca, Alice
  • Gómez-Llonín, Andrea
  • Rivas, Elisa
  • Linares, Jenniffer
  • Garrido, Marta
  • Sallent-Aragay, Anna
  • Recort-Bascuas, Alba
  • Comerma Blesa, Laura, 1983-
  • Rovira, Ana
  • Albanell Mestres, Joan
  • Calon, Alexandre
  • Labernadie, Anna
Immunotherapies are beneficial for a considerable proportion of cancer patients, but ineffective in others. In vitro modelling of the complex interactions between cancer cells and their microenvironment could provide a path to understanding immune therapy sensitivity and resistance. Here we develop MIRO, a fully humanised in vitro platform to model the spatial organisation of the tumour/stroma interface and its interaction with immune cells. We find that stromal barriers are associated with immune exclusion and protect cancer cells from antibody-dependent cellular cytotoxicity, elicited by targeted therapy. We demonstrate that IL2-driven immunomodulation increases immune cell velocity and spreading to overcome stromal immunosuppression and restores anti-cancer response in refractory tumours. Collectively, our study underscores the translational value of MIRO as a powerful tool for exploring how the spatial organisation of the tumour microenvironment shapes the immune landscape and influences the responses to immunomodulating therapies., We thank S. Usieto, S. Menendez Romero, D. Zafra Puerta, A. Menendez, D. Izquierdo Garcia, C. Rols, J. Durand for their technical assistance. A.L. acknowledges funding from “La Caixa” Banking Foundation (LCF/BQ/PR18/11640001) and from the Spanish Ministry for Science and Innovation MICIU/AEI /10.13039/501100011033 and “ERDF-EU A way of making Europe”, (PID2021-128635NB-I00), and “ESF Investing in your future”, (RYC2020/029736/I). This work was also supported by grants from Instituto de Salud Carlos III (ISCIII) co-funded by the European Union (EU) (PI17/00211, CP16/00151, PI20/00011; Spanish Ministry of Economy and Competitiveness) to A.C. A.C. is the recipient of Miguel Servet research contracts from Instituto de Salud Carlos III co-funded by the European Union (MS16/00151, CPII21/00012). J.A. acknowledges funding from the Generalitat de Catalunya (AGAUR 2021 SGR 00776), the CIBERONC (CB16/12/00241), and the ISCIII co-funded by the EU (PI21/00002). This work was also supported by the Plan de Recuperación, Transformación y Resiliencia (CNS2023-145267) co-funded by the European Union to A.C. P.R.-C. acknowledges funding from the Spanish Ministry of Science and Innovation (PID2022-142672NB-I00), the European Research Council (AdG 101097753), the Generalitat de Catalunya (2017-SGR-1602), and the prize ‘ICREA Academia’ for excellence in research. X.T. acknowledges funding from the Generalitat de Catalunya (AGAUR SGR-2017-01602), the CERCA Programme, the Spanish Ministry for Science and Innovation MICCINN/FEDER (PID2021-128635NB-I00 MCIN/AEI/ 10.13039/501100011033 and “ERDF-EU A way of making Europe”), European Research Council (Adv-883739), Fundació la Marató de TV3 (project 201903-30-31-32), European Commission (H2020-FETPROACT-01-2016-731957), La Caixa Foundation (LCF/PR/HR20/52400004 and ID 100010434 under the agreement LCF/PR/HR20/52400004); IBEC and IRB are recipient of a Severo Ochoa Award of Excellence from the MINECO. This work was also supported by Grant PT20/00023, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and the “Xarxa de Bancs de tumors” sponsored by Pla Director d’Oncologia de Catalunya (XBTC).